• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Melatonin vs Memantine for ECT-Related Cognitive Impairment

Melatonin vs Memantine for ECT-Related Cognitive Impairment

September 13, 2021
Anne Li, MD.
From The Carlat Hospital Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Anne Li, MD. Dr. Li has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Review of: Sarraf N et al, J Clin Neurosci 2020;74:146–150

Many patients hesitate to accept ECT because of the treatment’s adverse effects on cognitive function. Memantine (Namenda)—an NMDA receptor antagonist approved for the treatment of Alzheimer’s disease—has been shown to be more effective than placebo in preventing cognitive impairment due to ECT. A new study compares memantine with melatonin in depressed patients undergoing this treatment.

The authors conducted a randomized, double-blind trial to compare the effects of the two medications on patients with major depression who were undergoing ECT. Patients in the two medication groups were similar in demographic characteristics, duration of major depression, and scores on the Mini-Mental Status Examination (MMSE). All patients received right unilateral ECT with similar stimulus intensity, frequency, and duration. Melatonin was chosen as a comparative treatment because a previous study reported that it appeared effective at reducing ECT-induced cognitive impairment (Hamdieh M et al, Neurol Psych Brain Res 2017;24:30–34).

A total of 40 patients were randomized to receive either memantine 5 mg/day (n = 20) or melatonin 3 mg/day (n = 20), starting on the day of the first ECT treatment and ending on the day of the sixth treatment. ECT was administered every other day, and the trial lasted 12 days. The researchers administered the MMSE and item 3 of the MMSE—a measurement of immediate recall—a day before the first ECT treatment and again 24 hours after completion of the last ECT treatment.

At the conclusion of ECT, participants receiving memantine scored significantly higher than their baseline scores on both the MMSE and item 3 of the MMSE (p = 0.04 and p = 0.03, respectively). In contrast, participants’ scores in the melatonin group dropped on both measures compared to their baselines (MMSE, p = 0.3, and item 3 of the MMSE, p = 0.02).

Study subjects tolerated the medications well. A previous placebo-controlled study similarly found that memantine 5 mg/day reduced cognitive impairment following ECT (Abbasinazari M et al, Asian J Psychiatr 2015;15:5–9).

CHPR’s TAKE
Patients are often reluctant to accept ECT because of its effects on cognition. By prescribing memantine 5 mg/day, we may be able to forestall those effects and improve ECT’s acceptability. While previous research has found that melatonin also helps mitigate ECT-induced cognitive impairment, this study did not, possibly because the melatonin was administered in the morning and may have caused sedation.
Hospital Psychiatry
KEYWORDS cognitive-impairment ect melatonin memantine
    Anne Li, MD.

    Clozapine for Conduct Disorder in Schizophrenia

    More from this author
    www.thecarlatreport.com
    Issue Date: September 13, 2021
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Agitation, CHPR, October-November-December 2021
    Note From the Editor-in-Chief
    IM Olanzapine Plus Benzodiazepines: Safe or Unsafe?
    Can We Treat Depression by Targeting Inflammation?
    Faster Refeeding of Patients With Anorexia Nervosa Appears Safe
    Melatonin vs Memantine for ECT-Related Cognitive Impairment
    Rapid-Onset Treatment for Pedophilic Disorder
    Medications to Rapidly Treat Psychotic Agitation
    Anticholinergic Drugs and Risk of Cognitive Impairment and Dementia
    Treating Agitation in Patients with Dementia
    DOWNLOAD NOW
    Featured Book
    • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

      Treating Alcohol Use Disorder: A Fact Book (2023)

      All the tools and information needed to assess and treat your patients who are struggling with...
      READ MORE
    Featured Video
    • therapist_canstockphoto9201097.jpg
      General Psychiatry

      Using SAMe In Clinical Practice with Garrett Rossi, MD

      Read More
    Featured Podcast
    • canstockphoto104192710.jpg
      Hospital Psychiatry

      Management of Depression and Neurocognitive Impairment in Patients With HIV

      Strategies for the evaluation and management of HIV-associated mood and cognitive changes and potential drug interactions between psychiatric and antiretroviral medications. 

      Listen now
    Recommended
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report

    Contact

    info@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.